Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) (KIA)
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Imatinib mesylate
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring cKIT inhibition in Asthma, Efficacy of Imatinib in severe resistent asthma.
Eligibility Criteria
Inclusion Criteria:
- Patients 18-65 years of age, diagnosed with asthma for at least 1 year;
- Refractory asthma, defined as reporting that their asthma has not been completely controlled in the past 3 months despite continuous treatment with high-dose inhaled corticosteroids (ICS) and an additional controller medication, with or without continuous oral corticosteroids (OCS)
Exclusion Criteria:
- Current smoking or smoking history of greater than 10 pack-years
- Any other significant respiratory or cardiac disease, or the presence of clinically important comorbidities, including uncontrolled diabetes, uncontrolled coronary artery disease
- If subject cannot undergo bronchoscopy procedure due to safety reasons
- Previous treatment with Imatinib
- A history of acute heart failure or chronic left sided heart failure
- Uncontrolled systemic arterial hypertension
- History of major bleeding or intracranial hemorrhage
- History of immunodeficiency diseases, including HIV
- Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Diagnosis of Hepatitis B or C.
- History of alcohol abuse within 6 months of screening.
- History of illicit drug abuse within 6 months of screening.
- Regular use of anticoagulants (eg: Warfarin Sodium, Coumadin), amiodarone, carbamazepine, Cyclosporine, Rifampicin, or reverse transcriptase inhibitors
Sites / Locations
- University of Alabama
- Brigham and Womens Hospital
- Washington University School of Medicine
- Columbia University
- Cleveland Clinic
- Temple University
- University of Wisconsin
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Imatinib mesylate
Placebo
Arm Description
Group on active imatinib treatment
Group on Placebo treatment
Outcomes
Primary Outcome Measures
Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline
Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.
PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1).
Secondary Outcome Measures
Serum Total Tryptase
Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment
Bronchoalveolar Lavage (BAL) Fluid Tryptase Level
Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo
Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %
Number of Asthma Exacerbations
Number of asthma exacerbations experienced from randomization to study completion.
FEV1 in Liters
Change in FEV1 in treatment group compared to placebo group
FEV1%
Change in FEV1% of predicted
Morning Peak Flow Measurement
Change in patient-reported morning peak flow measurement (L/s)
Evening Peak Flow
Change in patient-reported evening peak flow measurement (L/s)
Fractional Exhaled Nitric Oxide (FeNO)
Change in Fractional Exhaled Nitric Oxide Measurement (ppb)
Asthma Control Questionnaire (ACQ)
Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5.
Asthma Quality of Life Questionnaire (AQLQ)
Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5.
Asthma Symptom Utility Index (ASUI)
Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09.
BAL Neutrophil %
Change in BAL neutrophil percentage from baseline
BAL Eosinophil %
Change in BAL eosinophil percentage
Bronchoalveolar Lavage (BAL) PGD2
Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months
Endobronchial Biopsy Total Tryptase-positive Mast Cells
Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months
Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells
Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months
Blood Eosinophils
Change in blood eosinophil count
Airway Wall Thickness
Change in airway wall thickness as assessed by computerized tomography (CT)
Airway Wall Area
Change in airway wall area as assessed by computerized tomography (CT)
Bronchoalveolar Lavage Histamine
Change in bronchoalveolar lavage histamine levels from baseline
Urinary Prostaglandin D2
Change in urinary Prostaglandin D2 levels from baseline
Bronchoalveolar Lavage Cysteinyl Leukotrienes
Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline
Urinary Leukotriene E4
Change in urinary leukotriene E4 levels from baseline
Change in Sputum Supernatant Differential, Supernatant Tryptase and IL-13
Change in sputum eosinophil and neutrophil percentage. Change in sputum supernatant tryptase as measured by ELISA. Change in sputum IL-13 level as measured by ELISA.
Change in Inflammatory Mediators in Exhaled Breath Condensate
Assessment of change in eicosanoids in the exhaled breath condensate
Change in Number of Self-Reported Asthma Symptom Free Days
Full Information
NCT ID
NCT01097694
First Posted
March 23, 2010
Last Updated
May 15, 2017
Sponsor
Brigham and Women's Hospital
Collaborators
Baim Institute for Clinical Research, National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT01097694
Brief Title
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
Acronym
KIA
Official Title
A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
August 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
Baim Institute for Clinical Research, National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.
Detailed Description
Severe asthmatics remain poorly controlled despite high doses of standard asthma therapy or even daily doses of systemic corticosteroids or their equivalent. They account for a large proportion of the morbidity and mortality associated with asthma. Features that seem to characterize many patients with this disorder include persistent inflammation, symptoms, and airway hyperresponsiveness in the face of corticosteroid therapy. Mast cells are powerful, long-lived tissue dwelling effector cells that are resistant to corticosteroid effects and have been implicated in the pathobiology of asthma. Mast cells in the airway smooth muscle have been found to be the major distinguishing difference between asthmatic and non-asthmatic eosinophil airway disease; and putative circulating mast cell progenitors are increased 5 fold in asthma. Stem cell factor (SCF) is critical to mast cell homeostasis and upregulation and has pleiotropic effects on mast cells and eosinophils . SCF levels are elevated in relation to asthma severity and SCF antibodies block hyperresponsiveness and inflammation and remodeling in murine asthma models. Imatinib, a specific tyrosine kinase inhibitor, inhibits cKit (Kit), the receptor for SCF on mast cells. Imatinib at doses equivalent to, or below, doses safely used in humans, also mimics or exceeds anti-SCF effects in the murine asthma model. Therefore we would like to know Does imatinib, an inhibitor of Kit, ameliorate severe asthma, in association with effects on lung mast cell phenotype and/or function?
Specific Aims of the study are:
Specific Aim 1: To investigate whether, in patients with persistent airway responsiveness and poor asthma control despite intensive asthma therapy, 24 weeks of imatinib therapy results in a reduction in airway responsiveness and in secondary indicators of asthma control, airway inflammation, and structural changes in the airways.
Patients will be treated with imatinib in a randomized, double-blind, placebo controlled trial. Assessments will include methacholine and AMP reactivity, airway function, symptoms, airway wall thickness by CT scan, analysis of induced sputum, non-invasive markers of airway inflammation, and bronchoscopy including endobronchial biopsy and bronchoalveolar lavage - all before and at the end of therapy.
Specific Aim 2: To investigate whether, in patients with persistent airway responsiveness and poor asthma control despite intensive asthma therapy, 24 weeks of imatinib therapy results in changes in airway mast cell population and/or phenotype.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
cKIT inhibition in Asthma, Efficacy of Imatinib in severe resistent asthma.
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
176 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Imatinib mesylate
Arm Type
Active Comparator
Arm Description
Group on active imatinib treatment
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Group on Placebo treatment
Intervention Type
Drug
Intervention Name(s)
Imatinib mesylate
Other Intervention Name(s)
Gleevec, Zoleta, Glivec, Ziatir
Intervention Description
Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline
Description
Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.
PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1).
Time Frame
Over 6 months from beginning of treatment
Secondary Outcome Measure Information:
Title
Serum Total Tryptase
Description
Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment
Time Frame
6 months after start of treatment
Title
Bronchoalveolar Lavage (BAL) Fluid Tryptase Level
Description
Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo
Time Frame
6 months after start of treatment
Title
Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %
Time Frame
6 months after start of treatment
Title
Number of Asthma Exacerbations
Description
Number of asthma exacerbations experienced from randomization to study completion.
Time Frame
Up to 24 weeks
Title
FEV1 in Liters
Description
Change in FEV1 in treatment group compared to placebo group
Time Frame
6 months after start of treatment
Title
FEV1%
Description
Change in FEV1% of predicted
Time Frame
6 months after start of treatment
Title
Morning Peak Flow Measurement
Description
Change in patient-reported morning peak flow measurement (L/s)
Time Frame
6 months after start of treatment
Title
Evening Peak Flow
Description
Change in patient-reported evening peak flow measurement (L/s)
Time Frame
6 months after start of treatment
Title
Fractional Exhaled Nitric Oxide (FeNO)
Description
Change in Fractional Exhaled Nitric Oxide Measurement (ppb)
Time Frame
6 months after start of treatment
Title
Asthma Control Questionnaire (ACQ)
Description
Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5.
Time Frame
6 months after start of treatment
Title
Asthma Quality of Life Questionnaire (AQLQ)
Description
Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5.
Time Frame
6 months after start of treatment
Title
Asthma Symptom Utility Index (ASUI)
Description
Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09.
Time Frame
6 months after start of treatment
Title
BAL Neutrophil %
Description
Change in BAL neutrophil percentage from baseline
Time Frame
6 months after start of treatment
Title
BAL Eosinophil %
Description
Change in BAL eosinophil percentage
Time Frame
6 months after start of treatment
Title
Bronchoalveolar Lavage (BAL) PGD2
Description
Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months
Time Frame
6 months after start of treatment
Title
Endobronchial Biopsy Total Tryptase-positive Mast Cells
Description
Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months
Time Frame
6 months after start of treatment
Title
Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells
Description
Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months
Time Frame
6 months after start of treatment
Title
Blood Eosinophils
Description
Change in blood eosinophil count
Time Frame
6 months after start of treatment
Title
Airway Wall Thickness
Description
Change in airway wall thickness as assessed by computerized tomography (CT)
Time Frame
6 months after start of treatment
Title
Airway Wall Area
Description
Change in airway wall area as assessed by computerized tomography (CT)
Time Frame
6 months after start of treatment
Title
Bronchoalveolar Lavage Histamine
Description
Change in bronchoalveolar lavage histamine levels from baseline
Time Frame
6 months after start of treatment
Title
Urinary Prostaglandin D2
Description
Change in urinary Prostaglandin D2 levels from baseline
Time Frame
6 months after start of treatment
Title
Bronchoalveolar Lavage Cysteinyl Leukotrienes
Description
Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline
Time Frame
6 months after start of treatment
Title
Urinary Leukotriene E4
Description
Change in urinary leukotriene E4 levels from baseline
Time Frame
6 months after start of treatment
Title
Change in Sputum Supernatant Differential, Supernatant Tryptase and IL-13
Description
Change in sputum eosinophil and neutrophil percentage. Change in sputum supernatant tryptase as measured by ELISA. Change in sputum IL-13 level as measured by ELISA.
Time Frame
baseline to 24 weeks
Title
Change in Inflammatory Mediators in Exhaled Breath Condensate
Description
Assessment of change in eicosanoids in the exhaled breath condensate
Time Frame
baseline to week 24
Title
Change in Number of Self-Reported Asthma Symptom Free Days
Time Frame
baseline to week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients 18-65 years of age, diagnosed with asthma for at least 1 year;
Refractory asthma, defined as reporting that their asthma has not been completely controlled in the past 3 months despite continuous treatment with high-dose inhaled corticosteroids (ICS) and an additional controller medication, with or without continuous oral corticosteroids (OCS)
Exclusion Criteria:
Current smoking or smoking history of greater than 10 pack-years
Any other significant respiratory or cardiac disease, or the presence of clinically important comorbidities, including uncontrolled diabetes, uncontrolled coronary artery disease
If subject cannot undergo bronchoscopy procedure due to safety reasons
Previous treatment with Imatinib
A history of acute heart failure or chronic left sided heart failure
Uncontrolled systemic arterial hypertension
History of major bleeding or intracranial hemorrhage
History of immunodeficiency diseases, including HIV
Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
Diagnosis of Hepatitis B or C.
History of alcohol abuse within 6 months of screening.
History of illicit drug abuse within 6 months of screening.
Regular use of anticoagulants (eg: Warfarin Sodium, Coumadin), amiodarone, carbamazepine, Cyclosporine, Rifampicin, or reverse transcriptase inhibitors
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elliot Israel, M.D
Organizational Affiliation
Brigham and Womens Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joshua Boyce, M.D
Organizational Affiliation
Brigham and Womens Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Brigham and Womens Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Temple University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
15196279
Citation
Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy. 2004 Jun;34(6):911-6. doi: 10.1111/j.1365-2222.2004.01975.x.
Results Reference
background
PubMed Identifier
1370529
Citation
Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med. 1992 Jan 1;175(1):237-44. doi: 10.1084/jem.175.1.237.
Results Reference
background
PubMed Identifier
12037149
Citation
Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002 May 30;346(22):1699-705. doi: 10.1056/NEJMoa012705.
Results Reference
background
PubMed Identifier
10233863
Citation
Campbell E, Hogaboam C, Lincoln P, Lukacs NW. Stem cell factor-induced airway hyperreactivity in allergic and normal mice. Am J Pathol. 1999 Apr;154(4):1259-65. doi: 10.1016/S0002-9440(10)65377-1.
Results Reference
background
PubMed Identifier
12149526
Citation
Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002 Aug;57(8):677-82. doi: 10.1136/thorax.57.8.677.
Results Reference
background
PubMed Identifier
17872493
Citation
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062-71. doi: 10.1164/rccm.200701-085OC. Epub 2007 Sep 13.
Results Reference
background
PubMed Identifier
11112161
Citation
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000 Dec;162(6):2341-51. doi: 10.1164/ajrccm.162.6.ats9-00. No abstract available.
Results Reference
background
PubMed Identifier
8630386
Citation
Lukacs NW, Kunkel SL, Strieter RM, Evanoff HL, Kunkel RG, Key ML, Taub DD. The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonary mast cell activation. Blood. 1996 Mar 15;87(6):2262-8.
Results Reference
background
PubMed Identifier
19264687
Citation
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.
Results Reference
background
PubMed Identifier
16483568
Citation
Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol. 2006 Mar 8;533(1-3):327-40. doi: 10.1016/j.ejphar.2005.12.067. Epub 2006 Feb 17.
Results Reference
background
PubMed Identifier
9221761
Citation
Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med. 1997 Jul 21;186(2):313-23. doi: 10.1084/jem.186.2.313.
Results Reference
background
PubMed Identifier
28514613
Citation
Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Laidlaw TM, Boyce JA, Israel E. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N Engl J Med. 2017 May 18;376(20):1911-1920. doi: 10.1056/NEJMoa1613125.
Results Reference
derived
Learn more about this trial
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
We'll reach out to this number within 24 hrs